Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5415- ASA,    The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review
- Review, Var, NA
TumMeta↓, COX1↓, TXA2↓, AntiAg↑, EMT↓, TumCMig↓, TumCI↓, AMPK↑, cMyc↓, PGE2↓, Dose↑, RadioS↑, PD-L1↓, E-cadherin↑, EMT↓, Slug↓, Vim↓, Twist↓, MMP2↓, MMP9↓, other↑,
5414- ASA,    Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
- Review, Var, NA
Risk↓, *toxicity↓, other↑, *COX1↓, TumCP↓, DNArepair↑, ChemoSen↑, other↓,
5413- ASA,    Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin
- Trial, Nor, NA
*cardioP↑, *other↝, *COX1↓, *TXA2↓,
5412- ASA,    Clinical Pharmacology of Aspirin
- Review, NA, NA
*COX1↓, *COX2↓, *cardioP↑, *BioAv↑, *BioAv↝, *Half-Life↓, Risk↓, *other↑, *AntiAg↑,
5411- ASA,    Mechanistic Insights into a Classic Wonder Drug—Aspirin
- Review, Var, NA
*COX2↓, *COX1↓, *Inflam↓, *cardioP↑, Risk↓,
5410- ASA,    Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study
- Study, CRC, NA
Risk↓, Dose↝, Risk↓,
5408- ASA,    An aspirin a day keeps cancer at bay
- Review, Var, NA
TumMeta↓, TXA2↓, *AntiAg↑, COX1↓,
5400- ASA,    Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
- Review, Nor, NA
Risk↓, *Inflam↓, *COX1↓, *AntiAg↑, *Half-Life↓, *BioAv↑,
5401- ASA,    Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15R-prostaglandins that inhibit platelet aggregation
- Review, Nor, NA
*AntiAg↑, *COX1↓,
5399- ASA,    Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
- Trial, Nor, NA
Risk↝, Risk↑, Risk∅, Risk↑, other↝,
5409- ASA,    Role of aspirin in cancer prevention
- Review, Var, NA
Imm↑, *Inflam↓, *AntiAg↑, *GutMicro↑, eff↑, TumMeta↓, angioG↓, Risk↓, Risk↓,
5402- ASA,    Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity
- Review, Var, NA
COX1↓, TumMeta↓, *Half-Life↓, *COX2↓, *TXA2↓,
5404- ASA,    Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway
- Study, CRC, NA
Risk↓, other↝, Dose↝, Risk↓, other↓, other↝, KRAS↓, other↓, other↓,
5405- ASA,    Exploring Aspirin’s Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence
- Review, Var, NA
Risk↓, COX1↓, PGE2↓, Inflam↓, *AntiAg↓, PI3K↓, Akt↓, Risk↓,
5406- ASA,    Adjuvant aspirin therapy and colorectal cancer survival
- Trial, CRC, NA
Dose↝, OS∅,
5407- ASA,    Low-dose aspirin reduces the risk of colorectal cancer recurrence in patients with resected PI3K-altered localised disease, according to the ALASCCA trial.
- Trial, CRC, NA
Dose↝, Risk↓,
5793- ASA,    Aspirin Recapitulates Features of Caloric Restriction
- in-vitro, Nor, NA
*CRM↑, *HATs↓, *NF-kB↓, *EP300↓,
2461- ASA,    Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
- Review, NA, NA
AntiAg↑, COX1↓, eff↑,
1028- ASA,    Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development
- vitro+vivo, Ovarian, NA
TumCP↓, TumW↓, PD-L1↓, Ki-67↓, H3K27ac∅, eff↑,
1096- ASA,    Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review)
- Review, NA, NA
TumMeta↓, COX1↓, CTC↓,
1304- ASA,    Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells
- in-vitro, CRC, NA - in-vivo, NA, NA
TumCP↓, Apoptosis↑, Bcl-2↓, BAX↑, IL10↓, LTA/TNF-β↓,
1369- Ash,    Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis
- in-vitro, Melanoma, U266
tumCV↓, Apoptosis↑, BAX↑, Cyt‑c↑, Bcl-2↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, ROS↑, eff↓,
1368- Ash,  Cisplatin,    Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’
- in-vitro, Colon, HT-29 - in-vitro, BC, MDA-MB-231
tumCV↓, *toxicity↓, ROS↑, mitResp↓, ChemoSen↑,
1366- Ash,    Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling
- in-vitro, BC, MCF7
ROS↑, P53↑,
1370- Ash,    Withaferin A induces mitochondrial-dependent apoptosis in non-small cell lung cancer cells via generation of reactive oxygen species
- in-vitro, Lung, A549
ROS↑, eff↓,
1371- Ash,    Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine
- in-vitro, AML, HL-60
ROS↑, MMP↓, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, eff↓,
1372- Ash,    Withaferin-A Induces Apoptosis in Osteosarcoma U2OS Cell Line via Generation of ROS and Disruption of Mitochondrial Membrane Potential
- in-vitro, OS, U2OS
Apoptosis↑, ROS↑, MMP↓, Casp3↑,
1373- Ash,    Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells
- in-vitro, Kidney, Caki-1
ER Stress↑, p‑eIF2α↑, XBP-1↑, GRP78/BiP↑, CHOP/DDIT3↑, eff↓,
1355- Ash,    Withaferin A-Induced Apoptosis in Human Breast Cancer Cells Is Mediated by Reactive Oxygen Species
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, Nor, HMEC
eff↑, mt-ROS↑, mitResp↓, OXPHOS↓, compIII↑, BAX↑, Bak↑, other↓, ATP∅, *ROS∅,
1356- Ash,    Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells
- in-vitro, CRC, HCT116
ROS↑, TumCCA↑, MMP↓, TumCG↓, Apoptosis↑, JNK↝,
1357- Ash,    Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vitro, GBM, GL26
TumCP↓, TumCCA↑, Akt↓, mTOR↓, p70S6↓, p85S6K↓, AMPKα↑, TSC2↑, HSP70/HSPA5↑, HO-1↑, HSF1↓, Apoptosis↑, ROS↑, eff↓,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, eff↑, ChemoSen↑, ChemoSen↑, eff↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,
1359- Ash,    Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
MMP↓, Alix/AIP‑1↓, ROS↑, Paraptosis↑, ER Stress↝,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP/DDIT3↑, p‑eIF2α↑, ICD↑, eff↑,
1361- Ash,  SRF,    Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells
- in-vitro, Liver, HUH7 - in-vivo, Liver, HUH7
TrxR↓, ROS↑, DNA-PK↑, ER Stress↑, Apoptosis↑, eff↓,
1362- Ash,  GEM,    Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A
- in-vitro, PC, PANC1 - in-vitro, PC, Hs766t
ChemoSen↑, ROS↑, Apoptosis↑, TumCMig↓, F-actin↓, YMcells↓, NF-kB↓,
1363- Ash,  doxoR,    Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, CaOV3 - in-vivo, NA, NA
ChemoSen↑, ROS↑, DNAdam↑, TumCCA↑, LC3B↑, TumCG↓, cl‑Casp3↑,
1364- Ash,    Withaferin a Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress
- in-vitro, Bladder, J82
cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, ROS↑, MMP↓, DNAdam↑, eff↓,
1365- Ash,    Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells
- in-vitro, Oral, Ca9-22 - in-vitro, Oral, CAL27
ROS↑, *toxicity↓, Apoptosis↑, TumCCA↑, MMP↓, p‑γH2AX↑, DNAdam↑, eff↓,
1367- Ash,    An anti-cancerous protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells
- in-vitro, BC, MDA-MB-231
Apoptosis↑, ROS↑, Bax:Bcl2↑, MMP↓, Casp3↑, TumCCA↑,
1181- Ash,    Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCMig↓, TumCI↓, EMT↓, p‑SMAD2↓, p‑SMAD3↓, p‑NF-kB↓,
1180- Ash,    Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis
- in-vitro, Liver, HepG2
IDH1↑, Glycolysis↓, P53↑, Hif1a↓,
1179- Ash,    Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCP↓, TumCMig↓, STAT3↓, TumVol↓, TumW↓,
1178- Ash,    Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor
- in-vitro, Nor, HUVECs - in-vivo, NA, NA
*VEGF↓, *angioG↓, *ascitic↓, *Sp1/3/4↓,
1177- Ash,    Withaferin A downregulates COX-2/NF-κB signaling and modulates MMP-2/9 in experimental endometriosis
- in-vivo, EC, NA
TumVol↓, MMP2↓, MMP9↓, NF-kB↓, COX2↓, NO↓, IL1β↓, IL6↓,
1176- Ash,    Metabolic Alterations in Mammary Cancer Prevention by Withaferin A in a Clinically Relevant Mouse Model
- in-vivo, NA, NA
TumVol↓, Apoptosis↑, Glycolysis↓, PKM2↓, PGK1↓, ALDOAiso2↓,
1174- Ash,    Withaferin A Suppresses Estrogen Receptor-α Expression in Human Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vivo, BC, MDA-MB-231 - in-vitro, BC, T47D
p‑P53↑, Apoptosis↑, ERα/ESR1↓,
1173- Ash,    Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling
- in-vitro, EC, K1 - in-vitro, Nor, THESCs
TumCP↓, *toxicity↓, Apoptosis↑, TumCCA↑, TumCMig↓, TumCI↓, p‑SMAD2↓, TGF-β↓, *toxicity↓,
1172- Ash,    Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
FASN↓, ACLY↓, ACC1↓, CPT1A↓, SREBP1↓,
1433- Ash,  SFN,    A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
eff↑, Bcl-2↓, BAX↑, tumCV↓, DNMT1↓, DNMT3A↓, HDAC↓,

Showing Research Papers: 901 to 950 of 7365
Prev Page 19 of 148 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7365

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Ferroptosis↑, 1,   HO-1↑, 1,   ICD↑, 1,   NRF2↓, 1,   OXPHOS↓, 1,   ROS↑, 17,   mt-ROS↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP∅, 1,   BCR-ABL↓, 1,   compIII↑, 1,   mitResp↓, 2,   MMP↓, 7,   Mortalin↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC1↓, 1,   ACLY↓, 1,   ALDOAiso2↓, 1,   AMPK↑, 1,   cMyc↓, 1,   CPT1A↓, 1,   FASN↓, 1,   Glycolysis↓, 2,   IDH1↑, 1,   PGK1↓, 1,   PKM2↓, 1,   SREBP1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 14,   BAD↑, 1,   Bak↑, 2,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Casp3↑, 2,   cl‑Casp3↑, 4,   cl‑Casp8↑, 1,   cl‑Casp9↑, 3,   Cyt‑c↑, 1,   Ferroptosis↑, 1,   JNK↝, 1,   Paraptosis↑, 1,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

AMPKα↑, 1,   p70S6↓, 1,   Sp1/3/4↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 5,   other↑, 2,   other↝, 3,   tumCV↓, 3,   YMcells↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 2,   p‑eIF2α↑, 2,   ER Stress↑, 3,   ER Stress↝, 1,   GRP78/BiP↑, 1,   HSF1↓, 1,   HSP70/HSPA5↑, 1,   HSP90↓, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNA-PK↑, 1,   DNAdam↑, 3,   DNArepair↑, 1,   DNMT1↓, 1,   DNMT3A↓, 1,   m-FAM72A↓, 1,   P53↑, 2,   p‑P53↑, 1,   cl‑PARP↑, 4,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 7,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cMYB↓, 1,   CSCs↓, 1,   EMT↓, 4,   H3K27ac∅, 1,   HDAC↓, 1,   mTOR↓, 1,   p85S6K↓, 1,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

Alix/AIP‑1↓, 1,   annexin II↓, 1,   AntiAg↑, 2,   E-cadherin↑, 1,   F-actin↓, 1,   Ki-67↓, 1,   KRAS↓, 1,   MMP2↓, 2,   MMP9↓, 2,   ROCK1↓, 1,   Slug↓, 1,   p‑SMAD2↓, 2,   p‑SMAD3↓, 1,   TGF-β↓, 1,   TumCI↓, 4,   TumCMig↓, 5,   TumCP↓, 7,   TumMeta↓, 6,   Twist↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   EGFR↓, 1,   Hif1a↓, 2,   NO↓, 1,   TXA2↓, 2,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 6,   COX2↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,   LTA/TNF-β↓, 1,   NF-kB↓, 2,   p‑NF-kB↓, 1,   PD-L1↓, 2,   PD-L1↑, 1,   PGE2↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 7,   Dose↑, 1,   Dose↝, 4,   eff↓, 9,   eff↑, 8,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CTC↓, 1,   EGFR↓, 1,   ERα/ESR1↓, 1,   IL6↓, 1,   Ki-67↓, 1,   KRAS↓, 1,   PD-L1↓, 2,   PD-L1↑, 1,  

Functional Outcomes(tgid=23) ⓘ

OS∅, 1,   Risk↓, 13,   Risk↑, 2,   Risk↝, 1,   Risk∅, 1,   TumVol↓, 3,   TumW↓, 2,  
Total Targets: 145

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS∅, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CRM↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HATs↓, 1,   other↑, 1,   other↝, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EP300↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↓, 1,   AntiAg↑, 5,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   TXA2↓, 2,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 6,   COX2↓, 3,   Inflam↓, 3,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 1,   Half-Life↓, 3,  

Clinical Biomarkers(tgid=22) ⓘ

ascitic↓, 1,   GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 3,   toxicity↓, 5,  
Total Targets: 24

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page